Headache Management in Older Adults with Metabolic and Psychiatric Comorbidities

Initial Evaluation and Rule‑Out of Secondary Causes

In older adults with bipolar disorder, PTSD, diabetes, and chronic kidney disease, clinicians should first exclude secondary headache causes such as medication overuse, hypertension, and cervical spine disease through targeted history and physical examination before initiating primary headache treatment; non‑pharmacologic therapies are preferred to avoid drugs that may worsen metabolic or renal function. 1

Physical therapy or aerobic exercise is recommended as the initial intervention for both tension‑type headache and migraine in patients with diabetes and chronic kidney disease, because these modalities provide preventive benefit without drug‑interaction risks and have no contraindications in this population. 1

Short‑acting analgesics such as ibuprofen 400 mg or acetaminophen 1000 mg can be used for acute episodes, but NSAIDs should be limited or avoided in chronic kidney disease, whereas acetaminophen is safer provided cumulative dosing is monitored. 1

For acute migraine attacks, acetaminophen, NSAIDs (used cautiously in chronic kidney disease), or combination products containing aspirin, acetaminophen, and caffeine are appropriate first‑line options; these agents relieve pain while respecting renal and metabolic considerations. 1

Angiotensin‑converting‑enzyme inhibitors (e.g., lisinopril) or angiotensin‑receptor blockers are advantageous because they control blood pressure, protect renal function, and have demonstrated efficacy in reducing episodic migraine frequency. 1
Magnesium supplementation, with appropriate renal monitoring, is effective for migraine prophylaxis and is considered safe in chronic kidney disease. 1

Topiramate, while effective for migraine prevention, may impair cognition in older adults and increase the risk of metabolic acidosis in those with chronic kidney disease. 1
Amitriptyline can prevent chronic tension‑type headache but carries anticholinergic side effects that are problematic in the elderly and may worsen glycemic control in diabetic patients. 1
Gabapentin is not recommended for episodic migraine prevention due to insufficient efficacy. 1

Calcitonin gene‑related peptide (CGRP) monoclonal antibodies (e.g., galcanezumab, fremanezumab, eptinezumab) and the oral CGRP antagonist atogepant are effective migraine preventive treatments with favorable safety profiles in patients with diabetes and chronic kidney disease, although cost considerations may limit use. 1

Renal function should be regularly monitored when patients receive NSAIDs or magnesium supplementation to detect any deterioration promptly. 1

Achieving therapeutic dosing of lamotrigine (typically 100–400 mg daily) in bipolar disorder may enhance overall functioning and indirectly lessen headache burden; lamotrigine does not increase diabetes risk, unlike some alternative mood stabilizers. 1